What are the 2026 guidelines for the management of pulmonary embolism?

2026 Pulmonary Embolism Guidelines

The 2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline represents the most current evidence-based approach to acute PE management, introducing a new clinical severity classification system and providing updated recommendations for diagnosis, risk stratification, and treatment. 1

Key Updates in the 2026 Guidelines

New Risk Classification System

The 2026 guidelines introduce the AHA/ACC Acute Pulmonary Embolism Clinical Categories, which provide more granular severity classification compared to previous systems 1. This enhanced classification improves precision in:

• Severity assessment
• Prognosis determination
• Therapeutic decision-making

Important caveat: While this new classification offers improved granularity, these categories still require validation in clinical practice 2.

Diagnostic Approach

The guidelines maintain evidence-based diagnostic strategies that align with established principles:

Clinical probability assessment comes first - Use validated prediction rules or clinical judgment before any testing 3.

D-dimer strategy:

• Measure D-dimers (preferably highly sensitive assay) only in patients with low or intermediate clinical probability 3
• Do NOT measure D-dimers in high clinical probability patients - a normal result does not safely exclude PE 3
• Negative D-dimer reliably excludes PE in low/intermediate probability patients 3

Imaging:

• CTPA is the recommended initial imaging modality for non-massive PE 4, 3
• Normal CTPA in low/intermediate probability patients excludes PE without further testing 3
• Do NOT perform CT venography as adjunct to CTPA 3
• Do NOT use MRA to rule out PE 3

Treatment Recommendations

Anticoagulation (First-Line for Most Patients)

The 2026 guidelines strongly favor direct oral anticoagulants (DOACs/NOACs) and low-molecular-weight heparins as preferred anticoagulants 1, 2.

For hemodynamically stable patients:

• Prefer NOACs (apixaban, dabigatran, edoxaban, or rivaroxaban) when initiating oral anticoagulation 3
• If parenteral anticoagulation needed initially, prefer LMWH or fondaparinux over UFH 3
• Alternative: VKA overlapping with parenteral anticoagulation until INR 2.0-3.0 (target 2.5) 3

Contraindications to NOACs:

• Severe renal impairment 3
• Antiphospholipid antibody syndrome (use VKA indefinitely) 3

For hemodynamically unstable/high-risk PE:

• Initiate UFH with weight-adjusted bolus injection without delay 3

Duration of Anticoagulation

All patients require >3 months of therapeutic anticoagulation 3.

Specific durations:

• Provoked PE (transient/reversible risk factor): Discontinue after 3 months 3
• First unprovoked PE: Minimum 3 months; consider indefinite therapy if low bleeding risk 3
• Recurrent unprovoked VTE: Continue indefinitely 3
• Cancer-associated PE: Consider LMWH for first 3-6 months, then continue indefinitely 3, 5, 3

Reassess regularly: Drug tolerance, adherence, hepatic/renal function, and bleeding risk at regular intervals for patients on extended anticoagulation 3.

Reperfusion Therapies

High-risk (massive) PE with hemodynamic instability:

• Administer systemic thrombolytic therapy as first-line treatment 3
• Surgical pulmonary embolectomy if thrombolysis contraindicated or failed 3
• Consider catheter-directed therapies where expertise available 4, 1, 6

Intermediate-risk (submassive) PE:

• Do NOT routinely administer systemic thrombolysis 3
• Anticoagulation is primary treatment 3
• Consider catheter-directed therapies in select cases 7, 1
• Administer rescue thrombolysis if hemodynamic deterioration occurs on anticoagulation 3

Important controversy: The 2026 guidelines suggest reperfusion therapies for scenarios currently lacking robust scientific evidence 2. Await results of ongoing clinical trials before widespread adoption of these expanded indications 2.

IVC Filters

Do NOT routinely use inferior vena cava filters 3. The evidence does not support routine prophylactic filter insertion, even for free-floating proximal DVT in adequately anticoagulated patients 5.

Special Populations

Pregnancy

• Perform formal diagnostic assessment with validated methods 3
• Administer therapeutic fixed-dose LMWH based on early pregnancy weight 3
• Do NOT use NOACs during pregnancy or lactation 3
• Do NOT insert spinal/epidural needle within 24 hours of last LMWH dose 3
• Do NOT administer LMWH within 4 hours of epidural catheter removal 3

Post-PE Care

Routinely re-evaluate all patients 3-6 months after acute PE 3.

Refer to CTEPH expert center if:

• Symptomatic patients with mismatched perfusion defects on V/Q scan beyond 3 months
• Consider echocardiography, natriuretic peptide, and/or cardiopulmonary exercise testing results 3

Implement integrated care model to ensure optimal transition from hospital to ambulatory care 3.

Systems of Care

The evolution toward Pulmonary Embolism Response Teams (PERT) and integration of AI detection systems have improved early recognition and coordination of care for intermediate and high-risk PE 6. This multidisciplinary approach emphasizes physiologic assessment including right ventricular function, pulmonary artery pressures, and cardiac output 6.